Intensive insulin therapy in patients with type 1 diabetes mellitus

Endocrinology and Metabolism Clinics of North America
Sean M SwitzerSatish K Garg

Abstract

There has been a significant increase in the prevalence of type 1 diabetes mellitus and type 2 diabetes mellitus in the past decade. The International Diabetes Foundation reported that there will be more than a half-billion people with diabetes by 2030, largely in emerging economies. Improved glucose control reduces microvascular and macrovascular complications and can be accomplished with intensive diabetes management. Continuous glucose monitors allow further improvement. The best way to emulate normal physiology is the development of an artificial pancreas. Early versions of closed-loop technology may be available in the United States in the next 3 to 5 years.

References

Jul 20, 2001·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·J L Selam
Jul 31, 2001·Lancet·M A Atkinson, G S Eisenbarth
Jul 12, 2002·Diabetes/metabolism Research and Reviews·Carla J Greenbaum
Jan 27, 2004·Advanced Drug Delivery Reviews·G M SteilK Rebrin
May 4, 2005·Journal of Diabetes and Its Complications·Irl B Hirsch, Michael Brownlee
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Satish K GargHeather Ulrich
Apr 13, 2006·JAMA : the Journal of the American Medical Association·Louis MonnierClaude Colette
Apr 22, 2006·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Robert E Ratner, UNKNOWN Diabetes Prevention Program Research
Feb 19, 2008·Diabetes Research and Clinical Practice·María I Del OlmoFrancisco Piñón
Apr 15, 2008·Endocrinology and Metabolism Clinics of North America·Samuel L EllisKenneth E Izuora
Jul 22, 2008·Diabetologia·S SteinerL Heinemann
May 16, 2009·Journal of Diabetes Science and Technology·Boris P KovatchevClaudio Cobelli
May 23, 2009·Diabetes Technology & Therapeutics·Daniel E VaughnGregory I Frost
Jul 21, 2009·Diabetes Technology & Therapeutics·Lisa K Gilliam, Irl B Hirsch
Nov 27, 2009·Diabetes Care·Elbert S HuangJames C Capretta
Feb 9, 2010·Diabetes Technology & Therapeutics·Irl B Hirsch, Carol A Verderese
Aug 18, 2010·International Journal of Clinical Practice. Supplement·S Garg, I B Hirsch
Apr 16, 2010·Science Translational Medicine·Firas H El-KhatibEdward R Damiano
Jun 11, 2010·Diabetes Technology & Therapeutics·Luigi Meneghini, Jane Sparrow-Bodenmiller
Jun 11, 2010·Diabetes Technology & Therapeutics·Irl B Hirsch
Jun 11, 2010·Diabetes Technology & Therapeutics·Henry Anhalt, Nancy J V Bohannon
Jun 11, 2010·Diabetes Technology & Therapeutics·David M MaahsH Peter Chase
Aug 11, 2011·Diabetes Technology & Therapeutics·Thomas DanneAndreas Thomas

❮ Previous
Next ❯

Citations

May 18, 2013·International Journal of Pharmaceutics·Ravinder Malik, Ipsita Roy
Aug 24, 2013·Diabetes Technology & Therapeutics·Viral N ShahSatish K Garg
Oct 18, 2013·Diabetes Technology & Therapeutics·Satish K GargViral N Shah
Dec 3, 2014·The Medical Clinics of North America·Elizabeth Stephens
Sep 23, 2016·Molecular Pharmaceutics·Bhagyesh R SarodeSimon H Friedman
Jan 25, 2018·Nutrients·Giorgia TasciniSusanna Esposito
Dec 5, 2012·Angewandte Chemie·Piyush K JainSimon H Friedman
Nov 7, 2019·Current Diabetes Reports·Simon H Friedman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

© 2021 Meta ULC. All rights reserved